PRO/CON debate: nonsteroidal (finerenone) vs. steroidal (spironolactone/ eplerenone) mineralocorticoid receptor antagonists in CKD: progress, pragmatism, and remaining uncertainties ca. 2026 from @ckj-era.bsky.social
#Nephpearls #Cardiorenal #NephSky

👉 pubmed.ncbi.nlm.nih.gov/42682722/

💊 Beyond glucose control: GLP-1 receptor agonists and SGLT2 inhibitors offer heart and kidney benefits in specific patient groups. An interesting time for multi-organ therapies and new indications.
www.nature.com/articles/s41...
#GLP1 #SGLT2 #CardioRenal #KidneyHealth

Kidney Health Guidance on Cardiovascular-Kidney-Metabolic (CKM) Syndrome ca. 2026 from @asnpublications.bsky.social
#Nephpearls #NephSky #Cardiorenal

👉 pubmed.ncbi.nlm.nih.gov/42684397/